Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.78 |
| ▸ | MAPT | P10636 | 8/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.73 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.53 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.53 |
| ▸ | ITGAL | P20701 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480195 | 1.00 | LMNA (0.78) | LMNAMAPTSMN1; SMN2L3MBTL1HTT | |
| SCHEMBL5483943 | 0.84 | MAPT (0.57) | LMNAMAPTSMN1; SMN2L3MBTL1HTT | |
| SCHEMBL5483941 | 0.84 | MAPT (0.57) | LMNAMAPTSMN1; SMN2L3MBTL1HTT | |
| SCHEMBL5485018 | 0.81 | LMNA (0.53) | LMNAMAPTSMN1; SMN2L3MBTL1HTT | |
| SCHEMBL5485023 | 0.81 | LMNA (0.53) | LMNAMAPTSMN1; SMN2L3MBTL1HTT | |
| SCHEMBL1399098 | 0.77 | LMNA (0.56) | LMNAMAPTSMN1; SMN2L3MBTL1HTT | |
| SCHEMBL1399100 | 0.77 | LMNA (0.56) | LMNAMAPTSMN1; SMN2L3MBTL1HTT | |
| SCHEMBL11618539 | 0.76 | CYP1A2 (0.66) | LMNAMAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL11618537 | 0.76 | CYP1A2 (0.66) | LMNAMAPTSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL5476029 | 0.75 | MAPT (0.76) | LMNAMAPTSMN1; SMN2L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | claimed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM3 | LMNA 3693/4885MAPT 1549/4885SMN1; SMN2 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.